Leaflet LEPTOPROL 5mg implant

Product code:
W69660001
Quantity:
1
Indicated for:
prostate cancer; breast cancer; endometriosis
Route of administration:
implantation
Substance:
leuprorelin (GnRH agonist)
ATC
L02AE02 — Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.

The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.

Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.

Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.

General data about LEPTOPROL 5mg

Substance:
leuprorelin
Date of latest medicines list:
01-06-2026
Product code:
W69660001
Concentration:
5mg
Pharmaceutical form:
implant
Quantity:
1
Product type:
Generic medicine
Price:
686.24 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
SANDOZ GMBH - AUSTRIA
Holder:
SANDOZ PHARMACEUTICALS S.R.L. - ROMANIA
Number:
12774/2019/01
Shelf life:
4 years

Concentrations available for leuprorelin

  • 11.25mg
  • 22.5mg
  • 3.75mg
  • 42mg
  • 45mg
  • 5mg
  • 7.5mg

Compensation lists for LEPTOPROL 5mg Sanpha

NHP 3 (C2) - NHP oncology

Price
686.24 RON
Copayment
686.24 RON
Patient
0.00 RON